Galapagos N.V. (GLPG)
Galapagos N.V. operates in the Biotechnology industry of the Healthcare sector, headquartered in Mechelen, BE. The stock last traded at $27.98, up 1.71% on the session, giving a market capitalisation of $1.84B. On trailing twelve-month figures it carries a trailing P/E of 3.28, a net margin of 46.8%. Its beta of 0.30 implies it has historically moved less than the broad market.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Galapagos N.V. is most often compared with the following Healthcare names: